SPOTLIGHT -
Pharmacological Management of Treatment-Resistant Anorexia Nervosa
Only 13% to 50% of AN patients are considered recovered 1 to 2 years posttreatment, and 20% to 30% go on to develop a chronic and unremitting course of AN. How can we improve these outcomes?
Treatment-Resistant Bulimia Nervosa: Clinical Implications and Future Directions
Dialectical behavior therapy may be particularly effective in mitigating biologically-driven vulnerabilities, and zonisamide and lamotrigine may play a role.
Pharmacological Treatment of Bulimia Nervosa
Bulimia nervosa is a disorder with a complex cause. The disorder is most commonly seen in women, generally with onset in adolescence.